Still, distinct cancer types harboring apparently unrelated tumor-driver mutations have been demonstrated to be positive for PD-L1 expression, making the PD-1/PD-L1 axis an excellent tumor-agnostic target [120,121]. This evidence concerns the gene CD274 and neoplasm.